Literature DB >> 24647824

Application of localized ³¹P MRS saturation transfer at 7 T for measurement of ATP metabolism in the liver: reproducibility and initial clinical application in patients with non-alcoholic fatty liver disease.

Ladislav Valkovič1, Martin Gajdošík, Stefan Traussnigg, Peter Wolf, Marek Chmelík, Christian Kienbacher, Wolfgang Bogner, Michael Krebs, Michael Trauner, Siegfried Trattnig, Martin Krššák.   

Abstract

OBJECTIVES: Saturation transfer (ST) phosphorus MR spectroscopy ((31)P MRS) enables in vivo insight into energy metabolism and thus could identify liver conditions currently diagnosed only by biopsy. This study assesses the reproducibility of the localized (31)P MRS ST in liver at 7 T and tests its potential for noninvasive differentiation of non-alcoholic fatty liver (NAFL) and steatohepatitis (NASH).
METHODS: After the ethics committee approval, reproducibility of the localized (31)P MRS ST at 7 T and the biological variation of acquired hepato-metabolic parameters were assessed in healthy volunteers. Subsequently, 16 suspected NAFL/NASH patients underwent MRS measurements and diagnostic liver biopsy. The Pi-to-ATP exchange parameters were compared between the groups by a Mann-Whitney U test and related to the liver fat content estimated by a single-voxel proton ((1)H) MRS, measured at 3 T.
RESULTS: The mean exchange rate constant (k) in healthy volunteers was 0.31 ± 0.03 s(-1) with a coefficient of variation of 9.0 %. Significantly lower exchange rates (p < 0.01) were found in NASH patients (k = 0.17 ± 0.04 s(-1)) when compared to healthy volunteers, and NAFL patients (k = 0.30 ± 0.05 s(-1)). Significant correlation was found between the k value and the liver fat content (r = 0.824, p < 0.01).
CONCLUSIONS: Our data suggest that the (31)P MRS ST technique provides a tool for gaining insight into hepatic ATP metabolism and could contribute to the differentiation of NAFL and NASH. KEY POINTS: • 1D localized (31) P MRS saturation transfer in the liver is reproducible at 7 T • NASH patients have decreased hepatic Pi-to-ATP exchange rate • In this study, hepatic metabolic activity correlates with liver fat content.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24647824     DOI: 10.1007/s00330-014-3141-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  28 in total

1.  Etiology and functional status of liver cirrhosis by 31P MR spectroscopy.

Authors:  Monika Dezortova; Pavel Taimr; Antonin Skoch; Julius Spicak; Milan Hajek
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

2.  In vivo 31P spectroscopy by fully adiabatic extended image selected in vivo spectroscopy: a comparison between 3 T and 7 T.

Authors:  W Bogner; M Chmelik; O C Andronesi; A G Sorensen; S Trattnig; S Gruber
Journal:  Magn Reson Med       Date:  2011-03-28       Impact factor: 4.668

3.  Abnormalities of the liver evaluated by 31P MRS.

Authors:  D J Meyerhoff; G S Karczmar; M W Weiner
Journal:  Invest Radiol       Date:  1989-12       Impact factor: 6.016

4.  In vivo (31)P magnetic resonance spectroscopy of the human liver at 7 T: an initial experience.

Authors:  Marek Chmelik; Michal Považan; Martin Krššák; Stephan Gruber; Martin Tkačov; Siegfried Trattnig; Wolfgang Bogner
Journal:  NMR Biomed       Date:  2014-02-24       Impact factor: 4.044

5.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

6.  Spectroscopic imaging with improved gradient modulated constant adiabaticity pulses on high-field clinical scanners.

Authors:  Ovidiu C Andronesi; Saadallah Ramadan; Eva-Maria Ratai; Dominique Jennings; Carolyn E Mountford; A Gregory Sorensen
Journal:  J Magn Reson       Date:  2010-01-28       Impact factor: 2.229

7.  Quantitative ATP synthesis in human liver measured by localized 31P spectroscopy using the magnetization transfer experiment.

Authors:  A I Schmid; M Chmelík; J Szendroedi; M Krssák; A Brehm; E Moser; M Roden
Journal:  NMR Biomed       Date:  2008-06       Impact factor: 4.044

8.  Integrated effects of multiple modulators on human liver glycogen phosphorylase a.

Authors:  Nacide Ercan-Fang; Mary C Gannon; Virginia L Rath; Judith L Treadway; Miriam R Taylor; Frank Q Nuttall
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-07       Impact factor: 4.310

9.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

10.  Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes.

Authors:  Albrecht Ingo Schmid; Julia Szendroedi; Marek Chmelik; Martin Krssák; Ewald Moser; Michael Roden
Journal:  Diabetes Care       Date:  2011-01-07       Impact factor: 19.112

View more
  15 in total

1.  Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly.

Authors:  Paul Fellinger; Peter Wolf; Lorenz Pfleger; Patrik Krumpolec; Martin Krssak; Kristaps Klavins; Stefan Wolfsberger; Alexander Micko; Patricia Carey; Bettina Gürtl; Greisa Vila; Wolfgang Raber; Clemens Fürnsinn; Thomas Scherer; Siegfried Trattnig; Alexandra Kautzky-Willer; Michael Krebs; Yvonne Winhofer
Journal:  JCI Insight       Date:  2020-03-12

2.  Rapid and simultaneous measurement of phosphorus metabolite pool size ratio and reaction kinetics of enzymes in vivo.

Authors:  Sang-Young Kim; Wei Chen; Dost Ongur; Fei Du
Journal:  J Magn Reson Imaging       Date:  2017-05-08       Impact factor: 4.813

Review 3.  Intracellular lipid accumulation and shift during diabetes progression.

Authors:  Peter Wolf; Yvonne Winhofer; Christian-Heinz Anderwald; Martin Krššák; Michael Krebs
Journal:  Wien Med Wochenschr       Date:  2014-07-22

4.  Phosphatidylcholine contributes to in vivo (31)P MRS signal from the human liver.

Authors:  Marek Chmelík; Ladislav Valkovič; Peter Wolf; Wolfgang Bogner; Martin Gajdošík; Emina Halilbasic; Stephan Gruber; Michael Trauner; Michael Krebs; Siegfried Trattnig; Martin Krššák
Journal:  Eur Radiol       Date:  2015-01-11       Impact factor: 5.315

Review 5.  [Functional MR imaging of the liver].

Authors:  A Wibmer; R Nolz; M Trauner; A Ba-Ssalamah
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

6.  Histogram analysis of gadoxetic acid-enhanced MRI for quantitative hepatic fibrosis measurement.

Authors:  Honsoul Kim; Seong Ho Park; Eun Kyung Kim; Myeong-Jin Kim; Young Nyun Park; Hae-Jeong Park; Jin-Young Choi
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

7.  Insulin Regulates Hepatic Triglyceride Secretion and Lipid Content via Signaling in the Brain.

Authors:  Thomas Scherer; Claudia Lindtner; James O'Hare; Martina Hackl; Elizabeth Zielinski; Angelika Freudenthaler; Sabina Baumgartner-Parzer; Klaus Tödter; Joerg Heeren; Martin Krššák; Ludger Scheja; Clemens Fürnsinn; Christoph Buettner
Journal:  Diabetes       Date:  2016-02-09       Impact factor: 9.461

8.  Detection and Alterations of Acetylcarnitine in Human Skeletal Muscles by 1H MRS at 7 T.

Authors:  Radka Klepochová; Ladislav Valkovič; Martin Gajdošík; Thomas Hochwartner; Harald Tschan; Michael Krebs; Siegfried Trattnig; Martin Krššák
Journal:  Invest Radiol       Date:  2017-07       Impact factor: 6.016

Review 9.  In-vivo31P-MRS of skeletal muscle and liver: A way for non-invasive assessment of their metabolism.

Authors:  Ladislav Valkovič; Marek Chmelík; Martin Krššák
Journal:  Anal Biochem       Date:  2017-01-21       Impact factor: 3.365

10.  Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease.

Authors:  Stefan Traussnigg; Emina Halilbasic; Harald Hofer; Petra Munda; Tatjana Stojakovic; Günter Fauler; Karl Kashofer; Martin Krssak; Michael Wolzt; Michael Trauner
Journal:  Wien Klin Wochenschr       Date:  2020-09-15       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.